Natco Pharma anticipates India, Brazil, Canada markets to be revenue drivers for FY20

...India is expecting about eight to 10 launches this year. Brazil we are expecting about three to four launches. Canada also we are expecting about three to four launches that is the major one, Nannapaneni said.

The company has recorded consolidated total revenue of Rs 2,225 crore for the year ended on March 31, 2019, as against Rs. 2,242 crore in the previous year, a slight decline of less than 1 per cent year-over-year.

The net profit for the period on a consolidated basis was Rs.642.4 crore as against Rs.695 crore for the last year showing a decline of 7.6 per cent. The Indian business stood at Rs 735 crore while that of Canada and Brazil at Rs 96 crore and 33 crores respectively.

...overall what we are projecting is that we will grow by about 7 per cent to 8 per cent and in topline and also we are expecting that our profits also should grow by about 8 per cent to 10 per cent from where we are today, he said.

The growth would primarily better revenues from its drug Copaxone as projected by its marketing partner Mylan and also improved performance the rest of the world based on new product launches.

Read Also: Natco Pharma files ANDA for generic version of Bosentan tablets for oral suspension

Copaxone (glatiramer acetate injection) a multi-billion dollar drug and a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis.

Natco Pharma's marketing partner Mylan had already launched a generic version of the same drug in the US market in October 2017.